This paper is in the following e-collection/theme issue:

RCTs - Pilots/Feasibility Studies (non-eHealth) (35) HIV/AIDS/STI Prevention and Care (937)

Published on in Vol 9, No 4 (2020): April

Preprints (earlier versions) of this paper are available at https://preprints.jmir.org/preprint/15029, first published .
Testing a Real-Time Tenofovir Urine Adherence Assay for Monitoring and Providing Feedback to Preexposure Prophylaxis in Kenya (PUMA): Protocol for a Pilot Randomized Controlled Trial

Testing a Real-Time Tenofovir Urine Adherence Assay for Monitoring and Providing Feedback to Preexposure Prophylaxis in Kenya (PUMA): Protocol for a Pilot Randomized Controlled Trial

Testing a Real-Time Tenofovir Urine Adherence Assay for Monitoring and Providing Feedback to Preexposure Prophylaxis in Kenya (PUMA): Protocol for a Pilot Randomized Controlled Trial

Authors of this article:

Paul Drain1 Author Orcid Image ;   Kenneth Ngure2 Author Orcid Image ;   Nelly Mugo3 Author Orcid Image ;   Matthew Spinelli4 Author Orcid Image ;   Purba Chatterjee4 Author Orcid Image ;   Peter Bacchetti4 Author Orcid Image ;   David Glidden4 Author Orcid Image ;   Jared Baeten1 Author Orcid Image ;   Monica Gandhi4 Author Orcid Image
Article Authors Cited by (16) Tweetations (1) Metrics

Journals

  1. Vernon F, Morrow M, MaWhinney S, Coyle R, Coleman S, Ellison L, Zheng J, Bushman L, Kiser J, Galárraga O, Anderson P, Castillo-Mancilla J. Income Inequality Is Associated With Low Cumulative Antiretroviral Adherence in Persons With Human Immunodeficiency Virus. Open Forum Infectious Diseases 2020;7(10) View
  2. Mcinziba A, Wademan D, Viljoen L, Myburgh H, Jennings L, Decloedt E, Orrell C, van Zyl G, van Schalkwyk M, Gandhi M, Hoddinott G. Perspectives of people living with HIV and health workers about a point-of-care adherence assay: a qualitative study on acceptability. AIDS Care 2023;35(10):1628 View
  3. Jennings L, Kellermann T, Spinelli M, Nkantsu Z, Cogill D, van Schalkwyk M, Decloedt E, van Zyl G, Orrell C, Gandhi M. Drug Resistance, Rather than Low Tenofovir Levels in Blood or Urine, Is Associated with Tenofovir, Emtricitabine, and Efavirenz Failure in Resource-Limited Settings. AIDS Research and Human Retroviruses 2022;38(6):455 View
  4. Haberer J, Mugo N, Bukusi E, Ngure K, Kiptinness C, Oware K, Garrison L, Musinguzi N, Pyra M, Valenzuela S, Thomas K, Anderson P, Thirumurthy H, Baeten J. Understanding Pre-Exposure Prophylaxis Adherence in Young Women in Kenya. JAIDS Journal of Acquired Immune Deficiency Syndromes 2022;89(3):251 View
  5. Joseph Davey D, Nyemba D, Castillo‐Mancilla J, Wiesner L, Norman J, Mvududu R, Mashele N, Johnson L, Bekker L, Gorbach P, Coates T, Myer L. Adherence challenges with daily oral pre‐exposure prophylaxis during pregnancy and the postpartum period in South African women: a cohort study. Journal of the International AIDS Society 2022;25(12) View
  6. Joseph Davey D, Dovel K, Mvududu R, Nyemba D, Mashele N, Bekker L, Gorbach P, Coates T, Myer L. Pre-exposure Prophylaxis Recent Adherence With Real-Time Adherence Feedback and Partner Human Immunodeficiency Virus Self-Testing: A Pilot Trial Among Postpartum Women. Open Forum Infectious Diseases 2022;9(2) View
  7. Olanrewaju A, Sullivan B, Gim A, Craig C, Sevenler D, Bender A, Drain P, Posner J. REverSe TRanscrIptase chain termination (RESTRICT) for selective measurement of nucleotide analogs used in HIV care and prevention. Bioengineering & Translational Medicine 2023;8(1) View
  8. Graham S, Okall D, Mehta S, Obondi E, Ng’ety G, Ochieng E, Jadwin-Cakmak L, Amico K, Harper G, Bailey R, Otieno F. Challenges with PrEP Uptake and Adherence Among Gay, Bisexual, and Other Men Who Have Sex with Men in Kisumu, Kenya. AIDS and Behavior 2023;27(4):1234 View
  9. Kiptinness C, Naik P, Thuo N, Malen R, Dettinger J, Pintye J, Rafferty M, Jomo E, Nyamasyo N, Wood T, Isabelli P, Morris S, Hattery D, Stergachis A, Were D, Sharma M, Ngure K, Mugambi M, Ortblad K. Online HIV prophylaxis delivery: Protocol for the ePrEP Kenya pilot study. Frontiers in Public Health 2023;11 View
  10. Haberer J, Mujugira A, Mayer K. The future of HIV pre-exposure prophylaxis adherence: reducing barriers and increasing opportunities. The Lancet HIV 2023;10(6):e404 View
  11. Louart S, Hedible G, Ridde V. Assessing the acceptability of technological health innovations in sub-Saharan Africa: a scoping review and a best fit framework synthesis. BMC Health Services Research 2023;23(1) View
  12. Zewdie K, Kiweewa F, Ssebuliba T, Morrison S, Muwonge T, Boyer J, Bambia F, Badaru J, Stein G, Mugwanya K, Wyatt C, Yin M, Mujugira A, Heffron R. The effect of daily oral PrEP use during pregnancy on bone mineral density among adolescent girls and young women in Uganda. Frontiers in Reproductive Health 2024;5 View
  13. Spinelli M, Gandhi M. Point-of-care urine tenofovir monitoring of adherence to drive interventions for HIV treatment and prevention. Expert Review of Molecular Diagnostics 2024;24(3):169 View
  14. Else L, Dickinson L, Edick S, Zyhowski A, Ho K, Meyn L, Dilly-Penchala S, Thompson B, Shaw V, Khoo S, Brand R. Tenofovir, emtricitabine, lamivudine and dolutegravir concentrations in plasma and urine following drug intake cessation in a randomized controlled directly observed pharmacokinetic trial to aid point-of-care testing. Journal of Antimicrobial Chemotherapy 2024;79(7):1597 View
  15. Gandhi M, Glidden D, Chakravarty D, Wang G, Biwott C, Mogere P, Maina G, Njeru I, Kiptinness C, Okello P, Spinelli M, Chatterjee P, Velloza J, Ogello V, Medina-Marino A, Okochi H, Mugo N, Ngure K. Impact of a point-of-care urine tenofovir assay on adherence to HIV pre-exposure prophylaxis among women in Kenya: a randomised pilot trial. The Lancet HIV 2024;11(8):e522 View
  16. Okello P, Velloza J, Ogello V, Owidi E, Mogere P, Gakuo S, Chakravarty D, Biwott C, Chatterjee P, Mugo N, Gandhi M, Ngure K. Acceptability and feasibility of a urine-based tenofovir adherence assay for monitoring and providing feedback on PrEP adherence in Kenya. AIDS Care 2025;37(2):324 View